Wen Luo

Dr. Luo has over 20 years of experience in the biomedical industry. Before founding Denovo Biopharma, Dr. Luo worked at Ligand Pharmaceuticals, where he led and participated in the development and research of multiple second-generation nuclear hormone receptors modulating drugs, engaged in the molecular mechanism of hormone receptors, tissue and organ selectivity, and drug screening, trials establishment, and is responsible for formulating and implementing biomarker strategies for multiple drugs at different stages of development. He was also responsible for the development of new protease drug targets in Corvas. At Incyte Genomics, Dr. Luo was involved in the management at the time of the world's largest proteome database LifeProt and engaged in new drug target gene and their splice variants For research and development. He was also engaged in the development and identification of new drug targets in the fields of cancer, immune disease, and angiogenesis at Sugen. He served as a postdoctoral fellow in the University of California, San Francisco Howard - Hughes Medical Institute. Dr. Luo has his Ph.D. in molecular biology and a doctorate in biochemistry, Indiana University.